A study of multinucleated giant cells in esophageal cancer

Hui Wang, Junjie Zhou, Jun Li, Yiqun Geng, Pei Meng, Changchun Ma, Ziqi Zhu, Weifeng Zhang, Liangli Hong, Yan Quan, Jiacong Wei, Qiongyi Huang, You Zhou, Zuoqing Su, Xiaoqing Zhu, Chuangzhen Chen, Shaobin Chen, Jiang Gu*

*Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review

    8 Downloads (Pure)

    Abstract

    Objectives: To evaluate the occurrence, abundance, distribution, nature and clinical significance of multi-nucleated giant cell (MGC) in esophageal cancer.

    Materials and methods: MGCs were examined with conventional pathology, immunohistochemistry and immunofluorescence in 107 esophageal cancer tissues. The findings were correlated to pathological diagnosis and clinical behavior of the cancers.

    Results: MGCs were identified in 31.7% (34/107) of the cases. MGCs were positive for CD11c, CD11b, CD32, CD16, HLA-DR and MMP9, and negative for CD163, CD206 and CD64 giving a molecular profile of proinflammatory M1 but not immunosuppressive M2. MGCs were significantly related to decreased lymph node metastasis (p = 0.011), low pTNM stage (p = 0.044), favorable survival (p = 0.04), squamous cell cancer type rather than other histopathological subtypes (p = 0.020) and associated to better differentiation (p = 0.063).

    Conclusions: MGCs belong to M1 macrophage and perform phagocytosis and scavenging of cancer cells that would benefit patients' survival and could serve as a prognostic marker.

    Original languageEnglish
    Article number108600
    Number of pages8
    JournalClinical Immunology
    Volume222
    DOIs
    Publication statusPublished - Jan-2021

    Keywords

    • MGC
    • Macrophage polarization
    • Phagocytosis
    • Esophageal cancer
    • Prognosis
    • TUMOR-ASSOCIATED MACROPHAGES
    • IGG-FC
    • PROGRESSION
    • COMPLEMENT
    • MATRIX-METALLOPROTEINASE-9
    • POLARIZATION
    • ACTIVATION
    • EXPRESSION
    • PLASTICITY
    • RECEPTORS

    Cite this